Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.

Blood - 1 Aug 2008

Ellis Nathan A, Huo Dezheng, Yildiz Ozlem, Worrillow Lisa J, Banerjee Mekhala, Le Beau Michelle M, Larson Richard A, Allan James M, Onel Kenan

Abstract excerpt

The p53 tumor suppressor directs the cellular response to many mechanistically distinct DNA-damaging agents and is selected against during the pathogenesis of therapy-related acute myeloid leukemia (t-AML). We hypothesized that constitutional genetic variation in the p53 pathway would affect t-AML risk. Therefore, we tested associations between patients with t-AML (n = 171) and 2 common functional p53-pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Leukemia, Myeloid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms, Second Primary

Share to Polymorphism, Genetic

Share to Proto-Oncogene Proteins c-mdm2

Share to Risk Factors

Share to Sex Factors

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 18426989
DOI: 10.1182/blood-2007-11-126508
PMCID: PMC2481552

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.PMID 18426989Read ↗

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.Semantic proximity Read ↗

MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.Semantic proximity Read ↗

MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.Semantic proximity Read ↗

Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.Semantic proximity Read ↗

TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility.Semantic proximity Read ↗

Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.Semantic proximity Read ↗

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.Semantic proximity Read ↗

MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.Semantic proximity Read ↗

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.Semantic proximity Read ↗

Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia.Semantic proximity Read ↗

Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.Semantic proximity Read ↗

Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.